NASDAQ / LIVE COMPANY INTELLIGENCE

BridgeBio Oncology Therapeutics, Inc.

Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.

TICKERBBOT
CORENasdaq-listed company
WATCHEarnings + filings + operating news
STATUSContinuously updated
LIVE / BBOT COVERAGE

What’s moving BridgeBio Oncology Therapeutics, Inc. now

Current reporting with the operating signal separated from the noise.

01
Is BridgeBio Oncology Therapeutics, Inc. (BBOT) Stock a Rising Oncology Opportunity With KRAS G12C Therapy Potential?

Is BridgeBio Oncology Therapeutics, Inc. (BBOT) Stock a Rising Oncology Opportunity With KRAS G12C Therapy Potential?

Investors are testing whether BridgeBio Oncology Therapeutics, Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
02
BridgeBio Oncology Therapeutics, Inc. : BBOT

BridgeBio Oncology Therapeutics, Inc. : BBOT

The story matters when it changes BridgeBio Oncology Therapeutics, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
03
BridgeBio Oncology Therapeutics, Inc. (BBOT) Discusses Clinical Data Updates for BBO-8520, BBO-11818, and BBO-10203 Transcript

BridgeBio Oncology Therapeutics, Inc. (BBOT) Discusses Clinical Data Updates for BBO-8520, BBO-11818, and BBO-10203 Transcript

The story matters when it changes BridgeBio Oncology Therapeutics, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
04
BridgeBio Oncology Therapeutics, Inc.

BridgeBio Oncology Therapeutics, Inc.

The story matters when it changes BridgeBio Oncology Therapeutics, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
PRIMARY DOCUMENTS / SEC EDGAR

Latest BBOT filings.

Investor-relevant reports are shown first, followed by the company’s other recent official submissions.

10-QQuarterly financial reportFiled 2026-05-12 · Period 2026-03-31SEC ↗10-QQuarterly financial reportFiled 2025-11-12 · Period 2025-09-30SEC ↗10-KAnnual financial reportFiled 2026-03-05 · Period 2025-12-31SEC ↗8-KMaterial company eventFiled 2026-06-22 · Period 2026-06-16SEC ↗8-KMaterial company eventFiled 2026-05-12 · Period 2026-05-12SEC ↗8-KMaterial company eventFiled 2026-04-29 · Period 2026-04-27SEC ↗DEF 14AProxy and shareholder meetingFiled 2026-04-28 · Period 2026-06-16SEC ↗4Official SEC filingFiled 2026-07-06 · Period 2026-07-01SEC ↗
EARNINGS / QUARTERLY TRACKER

BridgeBio Oncology Therapeutics, Inc., quarter by quarter.

Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.